Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update
By Y. Liaw, N. Leung, J. Kao, T. Piratvisuth, E. Gane, K. Han, R. Guan, G. Lau, S. Locarnini. Hepatology International, 2008
927 citations recorded by the source corpus.
Large amounts of new data on the natural history and treatment of chronic hepatitis B virus (HBV) infection have become available since 2005. These include long-term follow-up studies in large community-based cohorts or asymptomatic subjects with chronic HBV infection, further studies on the role of HBV genotype/naturally occurring HBV mutations, treatment of drug resistance and new therapies. In addition, Pegylated interferon α2a, entecavir and telbivudine have been approved globally. To update HBV management guidelines, relevant new data were reviewed and assessed by experts from the region, and the significance of the reported findings were discussed and debated. The earlier “Asian-Pacific consensus statement on the management of chronic hepatitis B” was revised accordingly. The key terms used in the statement were also defined. The new guidelines include general management, special indications for liver biopsy in patients with persistently normal alanine aminotransferase, time to start or stop drug therapy, choice of drug to initiate therapy, when and how to monitor the patients during and after stopping drug therapy. Recommendations on the therapy of patients in special circumstances, including women in childbearing age, patients with antiviral drug resistance, concurrent viral infection, hepatic decompensation, patients receiving immune-suppressive medications or chemotherapy and patients in the setting of liver transplantation, are also included.
Subfields: Epidemiology, Hepatology
View Paper: https://www.semanticscholar.org/paper/294d7e453e7f7c0e62a2fb6dc1fa62c967ee0f2b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Hepatology
Citations in the corpus
- Long‐term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B (2010, background): “Viral replication is now recognized as the key driver of liver injury and disease progression, so the primary aim of treatment for chronic HBV infection is longterm suppression of HBV replication to undetectable levels.(1,28,29) Entecavir is a potent HBV antiviral that, in comparison with lamivudine”
- Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update (2012, background): “The severity of liver fibrosis is a strong prognostic factor by itself, and it helps to identify patients who will benefit from antiviral therapy, assess response to antiviral therapy, determine the optimal time to start surveillance, and stratify the risk of HCC and hepatic decompensation [1, 55].”
- Chronic hepatitis B: Update 2009 (2009, neutral): “Gastroenterology 2004;126(7):1740-1749.”